Creative Medical Technology Holdings Announces World Health Organization Approval of “olastrocel” as INN for Lead Allogeneic Cell Therapy CELZ-201

About this update from Creative Medical Technology Holdings, Inc.

[{"type":"image","alt":"Creative Medical Technology Holdings, Inc.","displaySize":"","headline":null,"caption":"Creative Medical Technology Holdings, Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":43,"url":"https://media.zenfs.com/en/globenewswire.com/4f20fc41994fc07ca8de61005b80d4fe"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/GXuNPn9qVk4jpjMkZ_nOOA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTYwO2NmPXdlYnA-/https://media.zenfs.com/en/globenewswire.com/4f20fc41994fc07ca8de61005b80d4fe","width":300,"height":43}},"lazy":false},{"type":"text","content":"Global assignment of this unique name enhances international clarity, strengthens regulatory positioning, and supports olastrocel’s advancement across large unmet-need global markets","length":182,"tagName":"p"},{"type":"text","content":"PHOENIX, Dec. 02, 2025 (GLOBE NEWSWIRE) -- Creative Medical Technology Holdings, Inc. (NASDAQ: CELZ) (“Creative Medical” or the “Company”), a clinical-stage biotechnology company developing next-generation regenerative and immune cell therapies, today announced that the World Health Organization (WHO) has approved “olastrocel” as the International Non-Proprietary Name (INN) for the active cellular substance in CELZ-201, the Company’s lead allogeneic cell therapy also known as AlloStem®.","length":491,"tagName":"p"},{"type":"text","content":"The INN is the globally standardized, unique scientific name used by regulators, clinicians, researchers, and global markets to identify a therapeutic substance throughout its development and commercialization lifecycle. This assignment is a key global milestone that typically occurs as a program advances into later regulatory stages and requires unified international identification.","length":386,"tagName":"p"},{"type":"text","content":"“Securing the name ‘olastrocel’ marks an important advancement for our program,” said Timothy Warbington, President and CEO of Creative Medical. “A WHO-recognized INN is foundational for global development, medical adoption, and long-term scalability. It provides a cohesive scientific identity for the asset as we continue to execute on our clinical strategy in large markets with significant unmet medical needs.”","length":415,"tagName":"p"},{"type":"text","content":"Mr. Warbington continued, “From an investor perspective, this milestone reflects disciplined progr...

More updates from Creative Medical Technology Holdings, Inc.